Article Text

Download PDFPDF
Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All three authors have equally contributed to the preparation of the manuscript, the writing process and the review of the draft.

  • Funding J-YLR has received advisory board or speaker fees from Asahi-Kasei, Eli Lilly, IBSA-Genévrier, Nycomed-Takeda, PharmEvo, Radius Health, Roche, Servier, UCB, Will Pharma and Zodiac. OB has received grant support or consulting fees from Bayer, Genevrier, IBSA, Meda, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, SMB and TRB Chemedica. CC has received consultancy, lecture fees and honoraria from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Medtronic and Roche.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles